Semaglutide Weight Loss Results: Genetics & Biomarker Context

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Clinical trials of semaglutide injection report average weight loss of 10–15% of body weight over 68 weeks, but individual outcomes range widely from 5% to 22% depending on multiple biological and behavioral factors. This variability underscores why population averages alone do not predict personal results.

Understanding your own metabolic context—including genetic predispositions in GLP-1 signaling, insulin sensitivity biomarkers, and baseline body composition—can help frame realistic expectations and support a more personalized conversation with your healthcare provider about whether semaglutide aligns with your wellness goals.

Clinical Trial Evidence: What the Data Actually Shows

The STEP trials (Semaglutide Treatment Effect in People with obesity) enrolled over 4,600 participants and measured weight loss across 68 weeks. Participants receiving 2.4 mg weekly lost an average of 14.9% body weight compared to 2.4% in the placebo group. However, roughly 30% of participants achieved less than 10% loss.

Outcomes also depend on baseline body mass index, metabolic health, and adherence to dosing schedules. Participants with type 2 diabetes showed slightly different response patterns than those without diabetes, suggesting that underlying glucose metabolism influences semaglutide efficacy. Individual genetic variation in GLP-1 receptor expression may contribute to this heterogeneity.

Genetic and Biomarker Factors That Influence Semaglutide Response

Semaglutide works by activating GLP-1 receptors on cells throughout the body. Variations in the GLP1R gene (rs6923761) and other peptide-pathway genes affect how efficiently your cells respond to the medication. Individuals with certain genetic variants may experience faster satiety signaling or improved insulin sensitivity at lower doses.

Biomarker or Genetic Factor	Clinical Relevance to Semaglutide Response
GLP1R gene variant (rs6923761)	May influence baseline GLP-1 receptor sensitivity and dose response kinetics
FTO gene variant (rs9939609)	Associated with appetite regulation and metabolic rate; may affect weight-loss plateau timing
Baseline fasting insulin level	Higher insulin resistance may slow initial weight loss despite adequate medication adherence
Liver fat content & NAFLD status	Semaglutide improves hepatic steatosis; baseline severity may predict metabolic response trajectory
Gut transit time variability	Affects appetite suppression duration and consistency of dose effect throughout the day

Why Individual Weight Loss Outcomes Vary So Widely

Even with identical dosing and perfect adherence, two people may lose 8% and 18% body weight over the same timeframe. This variability reflects differences in appetite-regulation genetics, baseline metabolic rate, insulin secretion capacity, and how efficiently the gut releases hormones in response to food intake.

Lifestyle factors—diet quality, physical activity, sleep, and stress—interact with genetic predispositions. Someone with a favorable FTO variant genotype combined with consistent exercise may see accelerated loss, while genetic disadvantage paired with sedentary behavior may limit results even at maximum tolerated doses.

Who Is a Good Candidate, and When to Reassess Expectations

Semaglutide is indicated for adults with obesity (BMI ≥30) or overweight with weight-related conditions like type 2 diabetes or hypertension. However, candidacy also depends on gastrointestinal tolerance, absence of personal or family history of medullary thyroid cancer, and willingness to commit to long-term treatment, as weight typically returns after discontinuation.

If weight loss plateaus below 5% after 12 weeks at therapeutic dosing (2.4 mg weekly), discussing biomarker testing or genetic insights with your provider may help determine whether dose escalation, medication switching, or lifestyle intensification is appropriate. Compounded semaglutide from licensed 503A pharmacies offers a cost-effective starting point for exploring this pathway.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes to reveal your genetic predispositions within peptide-signaling pathways. This testing may help provide context for why your weight-loss trajectory might differ from population averages and should be interpreted with a qualified healthcare provider as one input—not a predictor of exact medication response.

The genetic test does not guarantee semaglutide will or will not work for you; rather, it identifies which peptide pathways your genes emphasize, helping frame conversations about expected response ranges, optimal dosing timelines, and whether combination approaches (like dual GLP-Squared compounds) might align with your genetic profile.

Understanding your peptide-pathway genetics can support a more informed conversation with your provider about realistic weight-loss expectations, optimal monitoring frequency, and whether compounded semaglutide, tirzepatide, or other GLP-1 approaches deserve trial in your personalized treatment plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.